树突状细胞浸润与肺癌预后相关性研究

Study on the relationship between the dendritic cell infiltration in cancer tissues and prognosis in patients with lung cancer

目的 研究肿瘤浸润树突状细胞 (TIDC)在肺癌组织中的数量 ,以及与肺癌生物学行为的关系和对预后的价值。方法 用免疫组化法检测 39例肺癌组织S_10 0蛋白表达水平 ,流式细胞仪检测S_10 0 +TIDC的数量及DNA倍体。结果 39例标本中S_10 0蛋白阳性表达率为 10 0 % ,S_10 0 +细胞具有典型树突状细胞形态学特征。异倍体肿瘤组织中S_10 0 +TIDC百分率为 2 1.81%± 8.18% ,明显高于二倍体肿瘤组织 ( 16 .0 3%±4.75 % )。有淋巴结转移组S_10 0 +TIDC百分率为 2 0 .43%± 7.74% ,无淋巴结转移组为 19.41%± 7.76 % ;肿瘤大于或等于 3cm组S_10 0 +TIDC百分率为 2 0 .90 %± 8.6 5 % ,小于 3cm组为 19.70 %± 7.6 1% ;非小细胞肺癌组S_10 0 +TIDC百分率为 19.48%± 7.98% ,小细胞肺癌组为 2 1.74%± 6 .17% ;存活期小于 1年组S_10 0 +TIDC百分率为 2 1.96 %± 8.0 5 % ,1～ 3年组为 19.47%± 6 .18% ,大于 3年组为 19.14 %± 8.76 %。经统计学分析 ,S_10 0 +TIDC数量与肿瘤大小、组织学类型、淋巴结转移情况及患者生存期之间均未见明显相关性。结论 TIDC数量在人类肺癌中不宜作为一个独立的预后指标。

Objective To study the correlation among the number of tumor-infiltrating dendritic cells (TIDC) in cancer tissues and biological behavior and prognosis in lung cancer patients. Methods S-100 protein expression level was determined in 39 patients with lung cancer by immunohistochemistry technique. The number of S-100 + TIDC and DNA ploidy were measured by means of flow cytometry. Results The rate of positive S-100 protein expression was 100% in 39 patients, S-100 + cells showed typical morphology of dendritic cells. The percentage of S-100 +TIDC in patients with heteroploid (21.81%±8.18%) was significantly higher than those with diploid (16.03%±4.75%) (P=0.006). There was no statistical difference between lymph node metastasis group (20.43%±7.74%) and no lymph node metastasis group ( 19.41% ±7.76%), between tumor size greater than 3?cm group ( 20.90% ±8.65%) and less than 3?cm group ( 19.70% ±7.61%), between non-small cell lung cancer group (19.48%±7.98%) and small cell lung cancer group (21.74%±6.17%). No correlation was found between survival time ( 1 year , 1--3 years, greater than 3 years, respectively) and percentage of S-100 +TIDC (21.96%±8.05%, 19.47%±6.18%, 19.14%±8.76%, respectively). Conclusion The number of TIDC should not be chosen as an independent prognostic criterion in human lung cancer.